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ABSTRACT (188/250 WORDS) 24 
 25 
The concept of ‘relative’ adrenal insufficiency during critical illness remains a highly debated disease 26 
entity. Several studies have addressed how to diagnose or treat this condition but have often yielded 27 
conflicting results, which further fuelled the controversy. The main reason for the controversy is the fact 28 
that the pathophysiology is not completely understood.  Recently, new insights in the pathophysiology of 29 
the hypothalamus-pituitary-adrenal axis response to critical illness were generated. It was revealed that 30 
high circulating levels of cortisol during critical illness are explained more by reduced cortisol breakdown 31 
than by elevated cortisol production. Cortisol production rate during critical illness is less than doubled 32 
during the day but lower than in healthy subjects during the night.  High plasma cortisol concentrations 33 
due to reduced breakdown in turn reduce plasma ACTH concentrations via feedback inhibition, which 34 
with time may lead to an understimulation and hereby a dysfunction of the adrenal cortex. This could 35 
explain the high incidence of adrenal insufficiency in the prolonged phase of critical illness.  36 
These novel insights have created a new framework for the diagnosis and treatment of adrenal failure 37 
during critical illness that has redirected future research.   38 
 3 
INTRODUCTION 39 
Adrenal insufficiency acquired during critical illness was first described in 1946 by Hans Selye. Since 40 
then numerous studies aimed at further understanding this complex disease. Later, the distinction was 41 
made between ‘absolute’ and ‘relative’ adrenal insufficiency in the critically ill.1-3 Absolute adrenal 42 
insufficiency as also diagnosed outside the Intensive Care Unit (ICU) by endocrinologists, is well 43 
characterized and understood and refers to a failing cortisol production. In contrast, relative adrenal 44 
insufficiency, a term that refers to a functional and likely transient deficiency acquired during critical 45 
illness and that implies an insufficiently activated adrenal cortex relative to the degree of stress, is a 46 
concept that is the subject of great controversy.4,5,6 It is generally accepted that a pronounced and 47 
sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis in response to critical illness is 48 
vital. This is based largely on results of animal experiments revealing that adrenalectomy increases 49 
mortality of sepsis.7 However, the underlying mechanisms of relative adrenal insufficiency during critical 50 
illness are incompletely understood, contributing to the ongoing controversy as to whether such a state 51 
exists.  52 
THE CONCEPT OF ADRENAL INSUFFICIENCY IN CRITICAL ILLNESS 53 
Absolute adrenal insufficiency in critical illness 54 
During critical illness, as well as outside the context of the intensive care unit, absolute adrenal 55 
insufficiency has many possible causes.1-3 Absolute adrenal insufficiency can be divided into primary, 56 
secondary and tertiary adrenal failure.  Primary adrenal insufficiency is caused by diseases of the 57 
adrenal cortex. Adrenal dysfunction due to impaired adrenocorticotropic hormone (ACTH) secretion 58 
because of pituitary abnormalities is labelled secondary adrenal insufficiency, while insufficient Arginine-59 
vasopressine (AVP) or corticotropin releasing hormone (CRH) secretion and function can cause tertiary 60 
adrenal insufficiency.  The most common cause of 61 tertiary adrenal insufficiency is long-term,  
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high-dose glucocorticoid therapy, which suppresses the HPA axis by negative feedback inhibition.1-3 62 
During critical illness, patients with a prior history of adrenal insufficiency are at risk of developing an 63 
Addisonian crisis triggered by the stress of the disease. Besides the risk due to pre-existing adrenal 64 
insufficiency, new onset absolute adrenal failure can be evoked by critical illness itself. For example, 65 
adrenal insufficiency can be due to adrenal hemorrhage or adrenal vein thrombosis, for which ICU 66 
patients may be at higher risk given the coagulation disorders present in many types of severe illnesses. 67 
In addition, several medications frequently used in ICU can affect cortisol production. Etomidate is one 68 
of these drugs and is known to suppress cortisol production, even after a single dose. Other drugs 69 
known to influence the HPA axis are azoles, anticoagulants, phenobarbital, phenytoin, rifampin, opioids, 70 
chlorpromazine and imipramine.8 71 
Absolute adrenal insufficiency should be suspected whenever otherwise unexplained hypovolemia 72 
and/or catecholamine-resistant hypotension is present, especially when this occurs in a patient who also 73 
has hyperpigmentation, hyponatremia or hyperkalemia. A low plasma cortisol concentration with or 74 
without a low plasma ACTH concentration and a suppressed cortisol response to an ACTH stimulation 75 
test are further indicative of such a diagnosis of absolute adrenal insufficiency. 76 
It is generally accepted that patients with an established diagnosis of primary or secondary adrenal 77 
failure or patients on chronic treatment with systemic glucocorticoids prior to critical illness should 78 
receive additional coverage with hydrocortisone to cope with the acute stress of the disease.9,10  79 
Also, patients who are diagnosed with an acute Addisonian crisis in the ICU are typically treated with 80 
high doses of glucocorticoids. This therapeutic strategy is based on the assumption that cortisol 81 
production during critical illness is several-fold increased as compared with during health. The 82 
conventional treatment proposes the administration of an IV bolus of 100 mg of hydrocortisone followed 83 
by 50 to 100 mg every 6 hours on the first day, 50 mg every 6 hours on the second day, and 25 mg 84 
every 6 hours on the third day, tapering to a maintenance dose by the fourth to fifth day.9,10 85 
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Relative adrenal insufficiency in critical illness 86 
When the degree of HPA-axis activation is assumed to be not enough to cover the need of cortisol to 87 
survive, even when plasma cortisol levels are still higher than during health, the condition has been 88 
labelled ‘relative adrenal insufficiency’ (RAI).4 More recently, the term 'critical illness-related 89 
corticosteroid insufficiency' (CIRCI)5,6 has been introduced, as such ‘relative failure’ during critical illness 90 
can occur at any level of the HPA-axis and/or may be due to resistance to cortisol in the peripheral 91 
target tissues.5,6 However, the possible underlying mechanisms remain highly debated.  92 
Pro-inflammatory cytokines have been suggested to induce target tissue resistance and to inhibit ACTH 93 
function.2,11,12 Furthermore, impaired blood supply to the anterior pituitary gland can evoke ischemia or 94 
necrosis, accumulation of nitric oxide or central neuropeptides, and hereby decreased ACTH secretion.3 95 
Additionally, several neuropeptides, oxidative stress, altered adrenal blood flow, cortisol precursor 96 
deficiency due to low circulating cholesterol levels or medications that suppress cortisol synthesis have 97 
also been suggested to play a role.8 Since cholesterol is produced in the liver, patients with liver 98 
diseases may have defective cholesterol production, which could increase the risk of adrenal 99 
insufficiency. Furthermore, the incidence of coagulopathy is higher in liver disease patients leading a 100 
higher risk of adrenal haemorrhage.13 Target tissue resistance to cortisol, the second part of the 101 
definition of CIRCI, refers to decreased glucocorticoid cellular uptake or suppressed expression or 102 
activation of the glucocorticoid receptor. Low corticosteroid binding globulin (CBG) levels and decreased 103 
CBG affinity may impair cortisol transport. Furthermore, glucocorticoid receptor (GR) expression levels 104 
and affinity of the GR for cortisol can be altered by critical illness.  105 
As for absolute adrenal insufficiency, initial diagnosis of suspected relative adrenal insufficiency starts 106 
with the clinical presentation. Hypotension refractory to fluid resuscitation and vasopressors may be 107 
signs of CIRCI, even when other symptoms of adrenal failure are absent.  Suggested diagnostic criteria 108 
for CIRCI in critically ill patients have been based 109 on one landmark study by Annane et al. who 
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identified a plasma cortisol incremental response <9 µg/dl (for conversion of cortisol to SI units (nmol/l) 110 
multiply by 27.6.) after the injection of 250 µg ACTH (for conversion of ACTH to SI units (pmol/l) multiply 111 
by 0.22) in the face of a high baseline plasma cortisol concentration (>34 µg/dl) as most discriminative 112 
for an increased risk of death.4 However, these findings have not been replicated by other investigators, 113 
which explains why there is currently no consensus on the diagnostic criteria for relative adrenal 114 
insufficiency.5 Furthermore, also the dose of ACTH that should be used for the ACTH stimulation test 115 
remains controversial. A dose of 250 µg of ACTH leads to supra-physiologic ACTH levels and could 116 
therefore overcome any ACTH resistance. Alternatively, a 1 µg stimulation dose has been suggested 117 
but the diagnostic value hereof has not been extensively investigated in critically ill patients and the 118 
results of the studies have been conflicting.14,15 119 
Other authors have suggested that the diagnosis of CIRCI can be made by a random total plasma 120 
cortisol concentration <10µg/dl during critical illness.5 However, total plasma cortisol concentration is 121 
derived from the result  of adrenal production, secretion, distribution, binding and elimination of cortisol.  122 
Also, cortisol is secreted in a pulsatile manner.16 Overall, it thus seems impossible to assess the adrenal 123 
cortisol secretion rate with a single random cortisol measurement. Furthermore, total plasma cortisol 124 
concentrations give little information about glucocorticoid function.  Only free cortisol can cross the cell 125 
membrane to exert its function by binding to the GR and consequently binding as a complex in the 126 
nucleus. The acute response to critical illness comprises an immediate fall in the circulating levels of the 127 
binding proteins, CBG and albumin, together with an altered CBG binding affinity, which occurs via the 128 
cleavage of CBG at the sites of inflammation or in the circulation evoked by fever.17-21 Plasma free 129 
cortisol has been suggested by other authors to be more appropriate than total plasma cortisol for the 130 
assessment of the HPA-axis functioning..22,23 However, plasma free cortisol assays are currently not 131 
readily available and normal ranges of plasma free cortisol during critical illness have not been defined. 132 
Additionally, increasing evidence from both animal and human experiments suggests that GR 133 
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availability in different tissues, the GR affinity and translocation are regulated during critical illness.24-29 134 
In septic patients, for example, the dominant negative β-isoform of the GR was induced from the onset 135 
of critical illness on, which downregulates glucocorticoid action.25 Given the impact of these changes on 136 
glucocorticoid function, they limit conclusions about ‘adequacy’ of cortisol availability during illness. 137 
Finally, a lack of accuracy and a high inter-assay variation in cortisol assays,30 further limits the use of 138 
on one cut-off value of cortisol in clinical practice to define CIRCI. It may be necessary to use mass 139 
spectrometry since this method is more accurate and less sensitive to confounders.31,32  140 
The most recent guidelines for the treatment of sepsis no longer recommend to use the ACTH 141 
stimulation test for the diagnosis of CIRCI.33 Instead, the guidelines suggest to use a random cortisol 142 
level <18 µg/dl in a patient with septic shock and clinical suspicion of adrenal failure as an indication for 143 
initiation of steroid therapy.33 These current recommendations are still largely based on expert opinion.  144 
Other experts have recently suggested to measure interstitial cortisol levels in critically ill patients to 145 
assess the amount of cortisol availability for target tissues.34,35 To this end, a microdialysis catheter is 146 
inserted into the subcutaneous adipose tissue. However, edema is frequently present in the critically ill, 147 
regional blood flow is variable and it is unclear what the subcutaneous adipose tissue tells the clinician 148 
about the other target tissues of interest in the critically ill.36 The usefulness of this invasive technique 149 
thus remains unclear.  150 
Perhaps even more controversial than the diagnostic criteria is the issue of when treatment of CIRCI 151 
with exogenous glucocorticoids is required and which doses should be used. This controversy is mainly 152 
fuelled by the conflicting results of two large randomized controlled trials (RCT). The first large trial by 153 
Annane et al.37 investigated 300 patients with septic shock on vasopressor therapy. All patients received 154 
an ACTH stimulation test and were randomly assigned to be treated with placebo or with 200mg 155 
hydrocortisone plus 50µg fludrocortisone per day for 7 days. The study showed that glucocorticoid 156 
treatment reduced the duration of vasopressor 157 therapy. There was no overall benefit on survival, 
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but in the subgroup of patients who showed a low cortisol incremental response to the ACTH stimulation 158 
test, the treatment reduced 28 days-mortality by an absolute 10%.  However, the relevance of this 159 
subgroup analysis has been questioned as well as the bias induced by widespread use of etomidate 160 
during this study. The repeat RCT also could not confirm this beneficial effect on survival of a treatment 161 
with hydrocortisone for septic shock. Indeed, this multi-center randomized-controlled double-blind trial 162 
included 499 patients and investigated the impact on 28 days-mortality of 200 mg hydrocortisone daily 163 
or placebo for 5 days after which a tapering period followed.38 This study revealed that hydrocortisone 164 
treatment increased blood pressure but did not improve survival, neither in the non-responders to ACTH 165 
stimulation, nor in the entire population. Moreover, an increased incidence of septic shock relapse was 166 
observed. However this study was also criticized, mainly for its early stop due to slow patient 167 
recruitment, which reduced the statistical power of the trial.  168 
A systematic review of all high quality RCT’s recently concluded that hydrocortisone therapy does not 169 
reduce mortality of severe sepsis.39 Recent guidelines now recommend, although with a weak level of 170 
confidence, to only treat patients with hypotension refractory to vasopressor or fluid resuscitation.  171 
A dose of 200 mg hydrocortisone via continuous infusion is advised, with a quick tapering down of the 172 
dose whenever vasopressors are no longer needed. The guidelines do not advise glucocorticoid 173 
treatment for patients with sepsis without shock.33 174 
BETTER UNDERSTANDING THE HPA-AXIS REGULATION DURING CRITICAL ILLNESS? 175 
Further optimization of diagnosis and treatment of critical illness-induced adrenal insufficiency clearly 176 
requires a better understanding of the HPA axis pathophysiology in this context.  177 
The stress response is considered to start at the level of the hypothalamus, with the release of CRH into 178 
the portal circulation, which stimulates the pituitary corticotrophs to secrete ACTH, in turn activating the 179 
production and release of cortisol in the adrenal cortex. Negative feedback inhibition by cortisol at the 180 
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level of CRH and ACTH can turn off this activation of the HPA-axis to regain homeostasis. Critical 181 
illness is considered to be a condition of severe physical stress and the typically high plasma free and 182 
total cortisol concentrations are assumed to be explained by such a stress-induced HPA axis activation 183 
with several-fold increased cortisol production. However, an observation which does not support such 184 
an HPA axis activation during critical illness is the low plasma ACTH. Vermes et al. showed that plasma 185 
ACTH concentrations in patients suffering from severe trauma or sepsis were only transiently elevated 186 
and after a few days dropped below those observed in healthy control subjects in the face of high 187 
plasma cortisol.40 Furthermore, in a more heterogeneous long-stay ICU patient population, plasma 188 
ACTH concentrations were found to be suppressed from day 1 in ICU throughout the first week of 189 
critical illness, again in the presence of high plasma cortisol.41 190 
This dissociation between ACTH and cortisol suggested that non-ACTH-mediated mechanisms regulate 191 
cortisol availability during critical illness. Theoretically, an increased sensitivity for ACTH might explain 192 
low ACTH and concomitantly high cortisol. However, since the incremental cortisol response to an 193 
ACTH stimulation test during critical illness is never increased and often low, this appears unlikely.4 The 194 
possible role of other non-ACTH stimulators of cortisol production in the adrenal cortex has often been 195 
suggested.12 Animal and cell culture studies investigated the role of cytokines, neuropeptides and other 196 
mediators of such an increased cortisol production. But since cortisol production had not been 197 
quantified in the context of modern intensive care until recently, the long-standing assumption of a 198 
several fold increased cortisol production during critical illness was based only on extrapolation from the 199 
increased circulating (free) cortisol levels. Recently cortisol production was quantified during critical 200 
illness with use of the gold standard deuterated cortisol tracer technique.41 This study showed that 201 
daytime cortisol production during critical illness was only twice that of healthy subjects, but found that 202 
cortisol breakdown was substantially reduced which resulted in a 5-fold longer half-life of cortisol and 203 
which explained the high plasma cortisol levels. (Figure 1) The reduced cortisol breakdown was 204 
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explained by suppressed expression and activity of A-ring reductases in the liver and by suppressed 205 
activity 11β-hydroxysteroid dehydrogenase type 2 in kidney.41 A subsequent study that used 206 
deconvolution analysis, taking the 5-fold longer cortisol half-life into account, showed that nocturnal 207 
cortisol secretion was actually lower than in healthy subjects.42 Hence, the 24h cortisol production rate 208 
in many critically ill patients with high plasma cortisol levels may not be much higher compared to 209 
healthy controls. 210 
In this concept, the low plasma ACTH concentrations may well be explained by negative feedback 211 
inhibition exerted by elevated plasma cortisol brought about by reduced cortisol breakdown.  If ACTH 212 
levels remain suppressed for an extended period of time, this could have adverse consequences for the 213 
integrity of the adrenal cortex, which would be relevant predominantly in the prolonged phase of illness.   214 
A study of adrenal cortex biopsies harvested post-mortem from acute and prolonged (7 days or more) 215 
critically ill patients and from sudden out of hospital deaths showed a very pronounced depletion of 216 
cholesterol esters and suppressed expression of ACTH-regulated genes in adrenal glands from 217 
prolonged, but not acute, critically ill patients.43 Unfortunately, given the nature of the study, blood 218 
samples were not available to correlate the observed changes with plasma ACTH and cortisol 219 
concentrations. However, these results are strikingly reminiscent of the phenotype of POMC-deficient 220 
mice, which suggests that a sustained lack of ACTH-effect on the adrenal cortex may indeed explain 221 
these findings.44 These changes in the adrenal cortex of prolonged ICU stay-patients also help to 222 
explain the reported 20-fold higher incidence of symptomatic adrenal insufficiency in critically ill patients 223 
being treated in the intensive care unit for more than 14 days.45 224 
A NEW CONTEXT IN WHICH TO RECONSIDER DIAGNOSIS AND TREATMENT OF ADRENAL 225 
INSUFFICIENCY DURING CRITICAL ILLNESS? 226 
The recent novel insights have reshaped the understanding of the HPA-axis regulation during critical 227 
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illness, but have also provided a new context in which to reconsider diagnosis and treatment of adrenal 228 
insufficiency in that setting. 229 
First, if a primary adrenal failure would be the reason for an insufficiently increased cortisol production 230 
and thus insufficiently increased plasma cortisol concentrations , one would expect a high plasma ACTH 231 
concentration, which has not been reported.40,41 Second, it was shown that the cortisol incremental 232 
cortisol response to an ACTH stimulation test in critically ill patients correlated positively with both 233 
cortisol production rate and cortisol plasma clearance.41 (Figure 2) Patients who revealed a low cortisol 234 
response to ACTH, below the threshold of absolute adrenal failure46 were the ones who also had the 235 
most reduced cortisol breakdown, whereas their cortisol production rate was still comparable to that of 236 
healthy subjects. This small piece of evidence could suggest that a low incremental cortisol response to 237 
an ACTH injection give little information about the adequacy of cortisol production but may reflect the 238 
degree of reduced cortisol metabolism leading to increased cortisol levels that exert a certain degree off 239 
negative feedback. This would be comparable to what is observed in patients who are treated with 240 
exogenous glucocorticoids for an extended time, as they also reveal a suppressed cortisol response to 241 
ACTH injection, in the face of very high levels of (exogenous) glucocorticoids.47 Third, the response to 242 
an ACTH stimulation test is poorly reproducible in critically ill patients48 and increasing evidence 243 
supports the hypothesis that adrenal function during critical illness is dynamic. Therefore, perhaps the 244 
use of repetitive measurements of plasma cortisol over time together with repetitive ACTH stimulation 245 
tests could shed more light on the nature of adrenocortical dysfunction in critically ill patients.  It has 246 
already been suggested that the cortisol responsiveness to ACTH restores after recovery of illness, 247 
while a decreasing cortisol response during repetitive ACTH-testing was associated with a poor 248 
prognosis.49-51 Unfortunately, large enough and well-designed prospective clinical studies of systematic 249 
ACTH stimulation tests performed on repeated time points into the prolonged phase of critical illness 250 
and recovery are currently lacking.  251 
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The use of repetitive cortisol measurements may be additionally important, taking into account the 252 
limitations of a single total or free cortisol measurement. If persistently low circulating ACTH levels lead 253 
to downregulation of ACTH signalling in the adrenal cortex,43 this could compromise adrenal function 254 
and preclude any additional cortisol to be produced whenever a next problem occurs during prolonged 255 
critical illness.  This would be reflected in a progressively lower plasma cortisol concentrations with time, 256 
coinciding with a lowering of the incremental cortisol response to an ACTH test.  Such a time course 257 
was already suggested by a recent small study that showed that plasma cortisol levels decreased in the 258 
prolonged phase of illness.52 259 
Also the time course of repetitive quantification of plasma ACTH, concomitantly measured with 260 
repetitive plasma cortisol and integrated with the results of repetitive ACTH tests, could be quite 261 
informative. Indeed, if sustained negative feedback inhibition by high cortisol that is not broken down 262 
play a role in the suppression of plasma ACTH during sustained critical illness, one could expect that 263 
plasma ACTH levels rise as soon as cortisol breakdown increases again with recovery. On the other 264 
hand when the ACTH levels remain low, the coinciding effect on the adrenal cortex would limit sufficient 265 
cortisol availability in the prolonged critically ill due to decreased cortisol production and may indicate 266 
who would benefit from treatment with hydrocortisone. (Figure 3) 267 
Recent insights indeed stress the importance of correctly identifying patients with a truly failing adrenal 268 
cortex for treatment. A recent animal study showed that corticosteroid treatment is only beneficial in 269 
septic mice with an absolute adrenal insufficiency, while it harmed the mice without such adrenal 270 
insufficiency.53 Besides the importance of accurately determining ‘who’ to treat, it also should be further 271 
investigated ‘how’ to best treat these patients. The currently proposed dose of 200 mg of hydrocortisone 272 
per day, referred to as “low dose” in the literature, is in fact between 3- to 6-fold higher than the cortisol 273 
production rate that was recently quantified in critically ill patients.41 Furthermore, given the 5-fold longer 274 
cortisol half-life in critically ill patients than in 275 healthy control subjects, the hydrocortisone doses 
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of 200 mg per day will expectedly result in high circulating (and possibly also tissue) cortisol levels 276 
during critical illness, with risks of side effects.41 Reducing cortisol breakdown may also be a clever 277 
mechanism during illness to regulate cortisol availability in a tissue-specific manner, directing high 278 
availability to those organs that express the cortisol metabolizing enzymes such as liver and kidney, 279 
while this could prevent too high levels of cortisol in those tissues that are susceptible to excessive 280 
glucocorticoid exposure such as skeletal muscle. Treatment with exogenous glucocorticoids in too high 281 
doses expectedly will increase cortisol availability in all tissues explaining the potentially deleterious 282 
effects of this treatment.54,55 In fact, the novel finding of an increased cortisol half-life during critical 283 
illness not only affects the decision on who and how to treat for adrenal failure, but should also be taken 284 
into account for treatment of ICU-patients with steroids for other indications. It is clear that more 285 
research is urgently needed to clarify the diagnostic and therapeutic implications of the novel 286 
pathophysiological insights.  287 
CAN PRELIMINARY RECOMMENDATIONS BE MADE?  288 
While we eagerly await well-designed clinical studies to provide more evidence on how to better 289 
diagnose and treat critically ill patients with adrenal failure, perhaps some empirical recommendations 290 
can be made.  During the acute phase of illness, there is little or no evidence to support the presence of 291 
“relative adrenal failure” requiring treatment. Long-stay patients with symptoms consistent with  adrenal 292 
failure and decreasing random plasma cortisol together with a progressively lowering of the cortisol 293 
response to repetitive ACTH stimulation tests could be at risk of suffering from critical illness-induced 294 
adrenal failure.  295 
The experimental guideline applied at the authors’ institution identifies patients at risk of having adrenal 296 
failure eligible for treatment by the following rule of thumb: critically ill patients with symptoms 297 
(unexplained vasoplegia and/or coma for example) who are in the ICU for more than 6 days, with 298 
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progressively decreasing plasma baseline cortisol concentrations that fall below 6 µg/dl and with a 299 
incremental cortisol response to an ACTH stimulation test (250 µg IV bolus) of less than 6µg/dl.  300 
Evidently, these specific threshold levels only apply to the institution’s assay (RIA from Immunotech, 301 
Prague, Czech Republic) and cannot be extrapolated to other assays without comparative validation 302 
studies.  303 
Regarding treatment, historical doses of 200 mg hydrocortisone per day are likely too high given the 304 
substantially increased cortisol half-life during critical illness. Based on the stable isotope studies39 it 305 
appears that a dose of approximately 60 mg of hydrocortisone, as extrapolated from the tracer study, 306 
may be interesting to investigate in future studies.  A tapering down to the lowest effective dose as soon 307 
as possible should be advised to limit any adverse effects of excessive amounts of glucocorticoids 308 
during critical illness. 309 
310 
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FIGURE LEGENDS 472 
 473 
Figure 1 474 
Panel A represents cortisol production in critically ill patients (N=11; grey bar) compared to controls 475 
(N=9; white bar)  476 
Panel B represents cortisol plasma clearance after a small dose of deuterated-cortisol tracer. Bar charts 477 
represent means and standard errors. Based on these results, 24h cortisol production was estimated 478 
and depicted with the arrows.  479 
Panel C-D  show mRNA and protein expression of 5β-reductase in liver of twenty controls (white bar) 480 
and 44 patients (gray bar). Bar charts represent means and standard errors. The mRNA data are 481 
expressed, normalized to GAPDH, as a fold difference from the mean of the controls. Protein data are 482 
expressed normalized for CK-18 protein expression, as a fold difference from the mean of the controls. 483 
Figure reproduced from Reduced Cortisol Metabolism during Critical Illness. Boonen E, Vervenne H, Meersseman P et al.  484 
2013 N Engl J Med 18:1477-1488. Copyright © (2013) Massachusetts Medical Society.  Reprinted with permission. 485 
 486 
Figure 2 487 
Panels A shows the correlation between Plasma Clearance of D4-cortisol with plasma cortisol 488 
responses, 60 minutes after ACTH injection (250µg) amongst patients (N=10).  489 
Panel B shows the correlation between cortisol production with plasma cortisol responses, 60 minutes 490 
after ACTH injection (250µg) amongst patients (N=10). 491 
The shaded area represents 95% confidence interval.  492 
Figure reproduced from Reduced Cortisol Metabolism during Critical Illness. Boonen E, Vervenne H, Meersseman P et al.  493 
2013 N Engl J Med 18:1477-1488. Copyright © (2013) Massachusetts Medical Society.  Reprinted with permission. 494 
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Figure 3 496 
Schematic overview of the HPA-axis regulation during critical illness, recovery or sustained critical 497 
illness.  498 
 499 
 500 
